Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | F13A1 | P00488 | 3/20 | 0.49 |
| ▸ | TGM2 | P21980 | 3/20 | 0.49 |
| ▸ | TGM1 | P22735 | 3/20 | 0.49 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | JAK1 | P23458 | 1/20 | 0.48 |
| ▸ | MMP1 | P03956 | 2/20 | 0.48 |
| ▸ | MMP3 | P08254 | 2/20 | 0.48 |
| ▸ | MMP7 | P09237 | 2/20 | 0.48 |
| ▸ | MMP9 | P14780 | 2/20 | 0.48 |
| ▸ | MMP13 | P45452 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL477390 | 0.93 | SMN1; SMN2 (0.62) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL19544727 | 0.86 | SMN1; SMN2 (0.60) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL19544794 | 0.86 | SMN1; SMN2 (0.60) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL477362 | 0.85 | SMN1; SMN2 (0.50) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL18692685 | 0.84 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL21806033 | 0.84 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL477391 | 0.84 | SMN1; SMN2 (0.60) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL21806020 | 0.84 | SMN1; SMN2 (0.60) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL1103930 | 0.84 | SMN1; SMN2 (0.60) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL10297355 | 0.81 | SMN1; SMN2 (0.67) | SMN1; SMN2NPC1RAB9ACYP2C19HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2411387-B1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY | VETDC INC (US) | 2015-08-19 | — | — | EP | disclosed |
| US-9108980-B2 | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy | VETDC, INC. (US) | 2015-08-18 | — | — | US | disclosed |
| US-20150038486-A1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY | ELANCO US INC. | 2015-02-05 | — | — | US | disclosed |
| US-8772287-B2 | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy | VETDC, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20130289016-A1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY | ELANCO US INC. | 2013-10-31 | — | — | US | disclosed |
| US-8461158-B2 | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy | PATHWAY THERAPEUTICS INC. (US) | 2013-06-11 | — | — | US | disclosed |
| EP-2411387-A2 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY | Pathway Therapeutics, Inc. (US) | 2012-02-01 | — | — | EP | disclosed |
| WO-2010110685-A2 | PYRIMDDINYL AND 1,3,5-TRIAZINYL BENZIMTOAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY | PATHWAY THERAPEUTICS LIMITED (NZ) | 2010-09-30 | — | — | WO | disclosed |
| US-20100249099-A1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY | PATHWAY THERAPEUTICS LIMITED (NZ) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249099-A1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY | PAICS, CCNI, TYMS | SMN1; SMN2 3054/4885NPC1 3089/4885RAB9A 3369/4885 |
| US-20150038486-A1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY | PAICS, CCNI, TYMS | SMN1; SMN2 3054/4885NPC1 3089/4885RAB9A 3369/4885 |
| US-20130289016-A1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY | PAICS, CCNI, TYMS | SMN1; SMN2 3054/4885NPC1 3089/4885RAB9A 3369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.